两性霉素B雾化吸入加局部灌注联合伏立康唑治疗侵袭性肺部真菌感染研究

Study on amphotericin B atomization inhalation plus local perfusion combined with voriconazole in the treatment of invasive pulmonary fungal infections

  • 摘要: 目的 观察两性霉素B雾化吸入加局部灌注联合伏立康唑治疗侵袭性肺部真菌感染(IPFI)的临床效果。 方法 选取80例IPFI患者作为研究对象,采用简单随机分组法分为对照组和研究组,每组40例。对照组患者常规采用伏立康唑静脉滴注治疗,观察组患者在对照组基础上,采用两性霉素B雾化吸入联合纤维支气管镜局部灌注治疗。比较2组临床疗效、治疗时间和不良反应发生情况。 结果 研究组治疗时间为(14.82±3.36)d, 显著短于对照组的(21.49±5.07)d(P<0.05); 研究组临床总显效率为82.50%, 显著高于对照组的60.00%(P<0.05); 研究组不良反应总发生率为22.50%, 低于对照组的32.50%, 但差异无统计学意义(P>0.05)。 结论 两性霉素B雾化吸入加局部灌注联合伏立康唑是治疗IPFI的安全有效手段。

     

    Abstract: Objective To observe the clinical effect of amphotericin B aerosol inhalation combined with local perfusion and voriconazole in the treatment of invasive pulmonary fungal infections(IPFI). Methods A total of 80 patients with IPFI were selected and divided into control group and study group by simple random grouping method, with 40 cases in each group. The control group was given intravenous infusion of voriconazole, while the observation group was treated with aerosol inhalation of amphotericin B and local perfusion by fiberbronchoscopy on the basis of the control group. The clinical efficacy, treatment time and adverse reactions were compared between the two groups. Results The duration of treatment in the study group was(14.82±3.36)days, which was significantly shorter than(21.49±5.07)days in the control group(P< 0.05). The total effective rate in the study group was significantly higher than that of the control group(82.50%versus 60.00%, P<0.05). The total incidence of adverse reactions in the study group was lower than that in the control group, but the difference was not statistically significant(22.50% versus 32.50%, P>0.05). Conclusion Aerosol inhalation of amphotericin B combined with local perfusion plus voriconazole is safe and effective in the treatment of IPFI.

     

/

返回文章
返回